Pharmaceutical Business Review
Anonymous User | Login

Vical Receives US Patent For Universal Influenza Vaccine Approach

Published: 03-Jun-2009

To provide protection against circulating seasonal strains and emerging pandemic strains of influenza viruses

Vical has received US Patent No. 7537768, covering the use of influenza virus gene sequences in a universal vaccine that could provide protection against circulating seasonal strains as well as emerging pandemic strains of influenza viruses.

Vical's DNA vaccine technology can induce both antibody and T-cell immune responses against the target portions of the virus, potentially providing a level of protection not available with conventional influenza vaccines.

In addition, a vaccine based on this approach may have the potential to provide protection against future pandemic threats from new strains of influenza viruses.

The follow-on NP and M2 DNA components could be used in a universal influenza vaccine with the potential to protect against a broad range of circulating or emerging influenza strains.

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

ADAPT Localization

The Translation and Localization Specialists ...

Anoto

Providing Unique Technology for Digital Pen and Paper ...

Aptuit

Drug Discovery and Development ...

Bachem

Process Development and Manufacturing of Peptides and Complex Organic Molecules as APIs ...

BaseCon

IT Pharma Solutions ...

Bioceros

Pre-Clinical Development of Monoclonal Antibodies and Generation of GMP-Ready Proteins ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Your IP at Risk in Collaborations!

Free white paper: Ten steps to protect your R&D investment within partnerships. ...

Why, When and How to Conduct 14C Human Studies

Several risk-based strategies to assess metabolites exist. Whatever the strategy chosen, t ...

Why CAPA Still Matters

This free white paper explores the needs and effectiveness of correct CAPA control, how to ...

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

Using the Mean Kinetic Temperature (MKT) As a Parameter to Determine Whether Perishable Goods Have Been Transported and Stored Correctly

Tecnosoft systems use MKT calculation to control the acquired values and report the user w ...

USB HotStart-IT for Real Time PCR

USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...

Related Companies

Vical Incorporated

Vical Incorporated (Vical) is a biopharmaceutical company which is principally engaged ...

GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a is a United Kingdom-based pharmaceutical, biological, a ...

Wyeth

Wyeth is engaged in developing and providing pharmaceuticals and healthcare products fo ...

Sanofi-Aventis

Sanofi-Aventis (Sanofi-aventis) is a global pharmaceutical company engaged in the resea ...

Suppliers Product News

Organisations Throwing Mobile Technology at Problems With Little Consideration of Actual User and Business Needs, Quocirca

Survey reveals detrimental impact on organisational effectiveness and IT expenditure in healthcare and finance across the UK, France, Germany and the US.

Digital Pen and Paper Technology Helps Accelerate Clinical Trials

Digital pen and paper technology captures handwritten clinical data electronically, quickly and securely to save time and cost in drug discovery process.

Aptuit Outlines 2010 Business Priorities at 28th Annual J.P. Morgan Healthcare Conference

Aptuit, Inc., a contract development and manufacturing company, today will provide an update on 2010 business priorities and discuss its integrated service offerings at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.

Aptuit Publishes Study which Demonstrates the Value of Early Insights into the Characterisation of Drug Compounds

New research on the solid-state characterisation of finasteride clearly outlines a systematic approach to characterising and monitoring active pharmaceutical ingredients

Aptuit Launches Program to Accelerate Early Stage Drug Development

Aptuit INDiGO™ accelerates drug development from pre-clinical candidate selection to regulatory filing on a fixed timeline and price

mondoBIOTECH and Bachem Agree Long-Term Cooperation on the Development of Peptides to Fight Rare Diseases

mondoBIOTECH and Bachem on 24 September announced the conclusion of a longterm cooperation.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address